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This paper investigates consumer perception on generic medicines in Australia. 
Specifically, it examines how consumer concern and consumer knowledge about 
counterfeit medicines influence attitudes towards generic prescription medicine and 
willingness to pay more for branded prescription medicines. A research model is 
developed together with an agenda of nine hypotheses that contain consumer concern, 
consumer knowledge, attitude towards PGM, willingness to pay more for branded 
PM, consumer trust in internet shopping, and likelihood not to purchase PGM from 
legitimate drug store or Internet. Theory of Reasoned Action (TRA) is used to explain 
the results based on the proposed research model in this study. Mail surveys are 
implemented to reach mature age population as the segment of the sample. Other 
relationship within the model and a number of implications for businesses will be 
discussed, suggestions for future research are reviewed and the main contributions of 
the study will also be delineated. 
 
INTRODUCTION 
The World Health Organization (WHO) estimates that up to 60% of drugs in some 
developing countries and up to 20% in some developed countries are counterfeits 
(Liang, 2006; WHO, 2010).More than 50 percent of medicines that purchased from 
Internet are counterfeit and some researchers suggest that currently 60 percent of 
online products are counterfeit or substandard (Howard, 2010). Internet has become a 
“grey” market for counterfeiters to reach consumers by using discount and greater 
discretion to attract consumers’ attention (Howard, 2010). Counterfeit drugs result in 
significant health risks for patients who can cause long term detriments and even 
death (Moken, 2003; Liang, 2006; Lybecker, 2007). While there are many studies 
done in this area (e.g. Moken, 2003; Liang, 2006; Lybecker, 2007), there is a dearth 
of research from the consumers perspective (Bian and Veloutsou, 2007; Staake, 
Thiesse, and Fleisch, 2009; Veloutsou and Bian, 2008).  
Counterfeit generic drugs have been found in developed countries (Liang, 2006; 
Lybecker, 2007; Lybecker, 2008). For example, China (PRC) has one of the highest 
incidences of counterfeit drugs (Moken, 2003; Lybecker, 2008; Wyld, 2008). There 
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are two overarching issues with respect to counterfeit drugs in China. First, consumers 
“unknowingly” purchase deceptive counterfeit drugs (Bloch et al., 1993; Liang, 
2006). These can be defined as drugs sold as pharmaceutical company brand name 
drugs, usually at a much lower price. These drugs may (a) contain a lesser amount of 
the real drug’s active ingredient (b) contain no active ingredient at all (c) compose of 
substances varying from talcum power to aspirin to poison (d) blatantly mimic the 
real drug, inclusive of the manufacturer’s labels, pamphlets, and purity seals but are in 
fact fakes (Moken, 2003). Second, consumers are confused if “generic brands” of 
drugs are in fact counterfeits (d’Astous and Gargouri, 2001; Lybecker, 2008). As 
such, the growing consumer concern and the lack of consumer knowledge have led to 
less than favourable attitudes towards counterfeiting (Bang et al., 2000; Liang, 2006; 
Marcketti and Shelley, 2009). In a state of consumer confusion, these issues may lead 
consumers to willingly pay more for genuine drugs. It can also be postulated that 
consumers are more likely to purchase genuine drugs and develop a reluctance to buy 
generic brands even from legitimate pharmacies. In the context of this study, 
consumers in Australia also have the same issues with respect to counterfeit 
medicines as well.  
 
RELEVANT LITERATURE, THEORY AND HYPOTHESES 
There is no research has been conducted in Australia to identify consumer perceptions 
on generic prescription medicines but there is little research in generic medicines in 
some countries including Australia. Based on previous literature, most of researchers 
found the price of generic medicines in Australia are more expensive than other 
countries such as USA and New Zealand because of lack of competition in the market 
(Searles, Jefferys, Doran, and Henry, 2007; Medications cost more in 
Australia, 2009). Therefore, PBS changed generic medicine regulation to lower 
generic medicines prices in Australia by getting subsidy from the government. 
According to Hassali, Kong and Stewart (2006), some general practitioners in 
Melbourne still have misconception about safety and efficacy of generic medicines 
because there is not enough education from government and generic medicine 
industry for general practitioners. This will have negative influence to utilization of 
generic medicines in Australia in the future. Chua. Hassali, Shafie and Awaisu (2010) 
found that general practitioners in northern state of Malaysia have fundamentally 
accepted the use of generic medicines but they still have concern regarding the safety 
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and quality of generic products because there is not enough education for general 
practitioners from the government to assure about generic products approval system 
in Malaysia concerning quality and safety. Malaysia government should clarify all the 
uncertainties about generic products to gain trust from general practitioners about the 
quality and safety of generic medicines. Sharrad and Hassali (2010) have found that 
consumers in Iraq still difficult to accept the use of generic medicines because of lack 
of knowledge on generic medicines. Additionally, low price of generic medicine 
become the main reason for consumers in Iraq to consume generic medicines. 
Therefore, education is very important to correct misconception about generic 
medicines for consumers in Iraq. Developing countries (e.g. Iraq and Malaysia) and 
modern country (e.g. Australia) have the same issues about misconception of generic 
medicines for general practitioners or consumers. It shows that government and 
generic medicine industry must give education about generic medicines in the society 
to correct misconception of generic medicines. 
To begin with, most generic medicine literatures only focus on general practitioners 
or pharmacists perception (Hassali, Kong, and Stewart, 2006; Hassali, Shafie, and 
Awaisu, 2010) but little research has done in consumer perception. Specifically, there 
is no study of consumer perspective in Australia about generic medicine. This gap can 
be considered to be done in this study to understand more consumer perception in 
generic medicine in Australia. Most of the researchers found that education is the 
most important factor that needs to be considered as there is misconception of generic 
medicine in consumer minds. Consumers also have confused about the difference 
between generic medicine and counterfeit medicine that lead consumer willingly to 
pay more for genuine medicine in the market (d’Astous and Gargouri, 2001; 
Lybecker, 2008).  
Most of consumer perception studies about generic medicines are done in qualitative 
studies (Sharrad and Hassali, 2010; Chua, Hassali, Shafie, and Awaisu 2010). 
Therefore, empirical study will be considered in this study to analyze consumer 
perception by using research model to explain the causal relationship among all 
variables in the research model. 
As mentioned earlier, more than 50 percent of medicines that sells on the Internet are 
counterfeit (WHO Facts, 2010). Therefore, consumer trust to purchase generic 
prescription medicines in internet shopping need to be studied to get better 
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understanding on why consumers still purchase medicine from the Internet although 
consumer should know the risk of it.  
Theory of Reasoned Action – The theory of reasoned action (TRA) (Fishbein and 
Ajzen, 1975) suggests that people consider the consequences of alternative behaviours 
before engaging in them, and that they choose to perform behaviours they associate 
with desirable outcomes. In Fishbein and Ajzen’s theory of reasoned action model, 
behaviours are determined by a person’s intention to perform the behaviour. The 
model suggests that behavioural intent is derived from two factors: (1) attitude 
towards the behaviour; and (2) subjective norms or perceived social pressure 
associated with the behaviour. The TRA has been used to support theoretical 
framework in many consumer behaviour studies (Mowen and Minor, 1998; Lee and 
Littrell, 2005; Summers et al., 2006; Phau, Teah, and Lee, 2009). Therefore, the 
theory highlights that the best predictor of behavior is “intention”. In this context of 
this study, consumer concern and consumer knowledge will act as beliefs or 
subjective norms that will affect willingness to pay more for branded prescription 
medicines as intention. 
Consumer concern - When consumers believe that there is a certain problem and 
they are concerned, they are more likely to adapt to consumer behaviour practices to 
assuage or solve the problem (Hines et al., 1986; Marcketti and Shelley, 2009). It was 
found that the greater the knowledge and concern about issues within the industry, it 
was related to greater support for more socially responsible businesses (Dickson, 
2000). Consumer concern in the counterfeiting context examines consumer concerns 
regarding labelling, the legitimateness of the supplier, the source of drug production, 
the country of origin, contamination of drugs, cost, penalties of being caught 
possessing counterfeit drugs, health risks, drug policy and regulations and effects of 
purchasing counterfeit prescription medicines (Moken, 2003; Liang, 2006). Therefore, 
it can be proposed that; 
H1a: Consumer concern about counterfeit medicine has a positive influence on the 
attitude towards generic prescription medicine. 
H1b: Consumer concern about counterfeit medicine has a positive influence on the 
willingness to pay more for trade name (branded) prescription medicines. 
Consumer Knowledge - The term is the cognitive representation of product-related 
experience in a consumer’s memory, which takes the form of a product schema and is 
likely to contain knowledge in the form of coded representations of brands, product 
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attributes, usage situations, general product class information, and evaluation and 
choice rules (Maheswaran, 1994; Marcketti and Shelley, 2009). Farhar (1996) states 
that consumer perceptions and preferences about the environment are influenced by 
both factual and faulty information. If consumers are more knowledgeable, they will 
have information that would better assist them in making their decisions. More 
knowledgeable consumers are also more willing to pay a higher price (Bang et al., 
2000). In the context of TRA, it makes sense that heightened knowledge about 
counterfeit medicine would lead to stronger beliefs about the positive consequence or 
benefits of generic prescription medicine. 
H2a: There is a positive relationship between consumer knowledge about counterfeit 
medicines and attitude towards generic prescription medicines. 
H2b: There is a positive relationship between consumer knowledge about counterfeit 
medicines and willingness to pay more for trade name (branded) prescription 
medicines. 
Attitudes towards generic prescription medicines (GPM) - Attitude towards the 
behaviour is stronger than attitudes towards an object as it will result in higher 
likelihood of purchasing. Attitudes are beliefs and perceptions of consumers. Some of 
the common beliefs and concerns about GPM are the quality and functionality 
aspects, the social consequences, and the legality of generic prescription medicines. 
These have been tested by other researchers to be the more common attitudes that 
consumers hold towards counterfeiting in general. The TRA proposes that attitudes 
towards a behavior are influenced by beliefs that the behavior leads to significant 
consequences. In this context of study, consumers with strong concern of positive 
consequence to not purchase counterfeit medicines were significantly more likely to 
indicate they would be willing to pay more to purchase trade name (branded) 
medicines (Bang et al., 2000). 
H3: There is a positive relationship between attitudes towards generic prescription 
medicines and willingness to pay more for trade name (branded) prescription 
medicines. 
Willingness to pay more for branded prescription medicines - The more that the 
consumer knows about the advantages of branded prescription medicines, they are 
more likely to pay more for it (Bang et al., 2000).  The willingness to pay more is a 
relevant measure and reflects the attitude towards the behaviour of consuming generic 
prescription medicines. If consumers have stronger beliefs about the positive 
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consequences of purchasing genuine prescription medicines, they will have a higher 
willingness to pay more for the genuine prescription medicines. Higher willingness to 
pay more for genuine prescription medicines will also lead to higher likelihood to not 
purchase generic prescription medicines from a legitimate drug store or from the 
Internet.  
H4a: Willingness to pay more for trade name prescription medicines has a positive 
influence to the likelihood to not purchase generic prescription medicines from a 
legitimate drug store. 
H4b: Willingness to pay more for trade name (branded) prescription medicines has a 
positive influence to the likelihood to not purchase generic prescription medicines 
from the Internet. 
Consumer trust in internet shopping - Trust can be defined as a set of specific 
relationship intention dealing primarily with integrity, benevolence, competence, and 
predictability of an Internet online retailer (Gefen, Karahanna, and Straub, 2003). 
Previous studies have shown that consumer generally will avoid shopping online if 
the online retailers cannot be trusted (Gefen, 2000; Jarvenpaa and Tractinsky, 1999). 
There is no study about consumer trust to purchase GPM in internet shopping that 
moderate willingness to pay more for trade name (branded) prescription medicines 
and the likelihood to not purchase generic prescription medicines from the Internet. 
H5: Consumer trusts in internet shopping is a moderation variable between 
willingness to pay more for purchase genuine prescription medicines and the 





The preceding literature review provides the basis for the proposed theoretical 
framework highlighting the consumer concern and consumer knowledge will affect 
consumers’ attitude towards PGM and willingness to pay more for branded 
prescription medicines. In addition, the model also shows the effects that willingness 
to pay more for branded prescription medicines and consumer trust with the 
likelihood of a consumer to not purchase PGM from Internet or legitimate drug store. 




The study offers a number of significant contributions. Theoretically, TRA will be 
introduced to develop a framework in which to examine consumer perception of PGM 
in Australia. Using the TRA, it will be one of the first studies in PGM to integrate a 
proven consumer behaviour model (Bang et al., 2000; Marcketti and Shelley, 2009). 
The most significant methodological contribution is the empirical method will be used 
in this study to fill in the research gaps and provide a more rigorous presentation. 
Additionally, SEM techniques approach will be used in this study as it is more 
appropriate technique for measurement and theory testing than traditional statistical 
techniques (Kline, 2005).. From a managerial perspective, education programs for 
consumers will be the “counter-measure” that leads the consumers to accept generic 
medicines in the market and correct the misconception about generic medicines. 
Particularly, government and generic medicine industry will work together to inform 
the benefit of generic medicines to consumers and government through online 
learning service or pharmacists consultation.  
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